Neuphoria Therapeutics (NEUP) Receivables (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Receivables for 7 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables rose 8675.58% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 8675.58% increase from a year earlier, with the FY2025 full-year figure at $12185.0, down 94.54% from the prior year.
• Receivables was $2.4 million for Q1 2026 at Neuphoria Therapeutics, up from $1.6 million in the prior quarter.
• Over five years, Receivables peaked at $4.9 million in Q2 2022 and troughed at $3516.0 in Q3 2025.
• A 5-year average of $982049.5 and a median of $219811.5 in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables tumbled 98.38% in 2025 and surged 8675.58% in 2026, its largest moves.
• Over 5 years, Receivables stood at $4.9 million in 2022, then sank by 91.17% to $429272.5 in 2023, then plunged by 91.25% to $37582.0 in 2024, then jumped by 4152.78% to $1.6 million in 2025, then soared by 50.99% to $2.4 million in 2026.
• The last three Receivables figures came in at $2.4 million (Q1 2026), $1.6 million (Q4 2025), and $3516.0 (Q3 2025), per Business Quant data.